Compare Amgen, Inc. (AMGN) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Match Group Inc — how do they compare? Amgen, Inc. trades at $412.21 (market cap $225.71B), while Match Group Inc trades at $36.82 (market cap $8.43B). The key difference: Amgen, Inc. is far larger — about 26.8× Match Group Inc's market cap, and Amgen, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| AMGN | MTCH | |
|---|---|---|
Market Cap | $225.71B | $8.43B |
Sector | Health | Media |
52-Week High | $417.20 | $41.24 |
52-Week Low | $271.18 | $28.90 |
Enterprise Value | $269.02B | $11.40B |
Dividend Yield | 2.42% | 2.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $410.95, up 1.51% today, near its pivot point of $408. The stock shows bullish momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $6.29 versus $5.62 expected. Revenue reached $36.75B in 2025, with a net income margin of 22.95%. Analyst consensus is bullish with a 58.98% buy rating, though the current price exceeds the consensus target of $394.69. Technical indicators signal an overbought condition with RSI above 75.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high valuation multiples, significant debt levels, and competitive pressures. The stock's proximity to resistance at $415 suggests near-term consolidation may occur, yet fundamental strength supports long-term upside potential for investors focused on biotech growth.
MTCH trades at $37.26, up 1.78% on the day, with a bearish technical signal and neutral oscillators. The stock shows mixed earnings performance, beating Q2 2026 EPS estimates but missing on revenue, as Tinder faces headwinds while Hinge grows. Strong profitability is evident with a 74.8% gross margin and 20.17% net income margin, though high debt levels remain a concern. Recent news highlights institutional buying interest amid ongoing business transformation.
The outlook is cautiously optimistic, supported by a consensus price target of $42.33 (13.6% upside) and no sell ratings. Key opportunities include Hinge's international expansion and Tinder's turnaround potential, but risks involve execution challenges, competitive pressures, and significant leverage. Earnings growth remains the primary catalyst for valuation re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
